Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more

Alibaba rose more than 3% after outlining plans for over 20GW of global data-center capacity by 2032 and launching its Zhenwu V900 chip. Vicor jumped 9% after raising its outlook for sequential Q3 revenue growth to more than 20% from nearly 10%, while On Holding gained over 6% on 2029 targets of at least CHF5.6 billion in sales, a 65% gross margin and a $1 billion buyback authorization. Offsetting the gains, Quest Diagnostics and Labcorp each fell more than 5% after CMS said Medicare laboratory-service payments have run 16% above private-payor rates and will be aligned lower.

Analysis

CMS rate normalization is a more durable earnings risk for DGX and LH than the initial selloff implies because it resets a high-margin reimbursement pool rather than merely reducing volumes. The key sensitivity is each company's Medicare fee-for-service mix and ability to offset through commercial pricing, test mix, and laboratory consolidation; absent offsets, a mid-teens reduction on the affected book could translate to roughly 2-4% pressure on consolidated EBIT. The 1-3 month catalyst is management quantification of the impact, while the 6-18 month second-order effect is accelerated lab-network rationalization and greater scale advantage for the two incumbents versus smaller independent labs.

BABA's infrastructure ambition should be valued as a capital-intensity question before it is treated as an AI-revenue catalyst. Building capacity at that scale would require very large multi-year commitments to power, servers, networking and cooling, potentially suppressing cloud free-cash-flow conversion unless utilization and enterprise AI monetization ramp quickly; the announced chip raises strategic optionality but is not yet evidence of competitive inference economics. Near term, this supports China AI infrastructure sentiment, but domestic power-equipment and data-center supply-chain beneficiaries may capture more certain revenue than BABA shareholders.

VICR's revised growth trajectory matters because high-performance power conversion can see disproportionate gross-margin and operating-leverage upside when AI/server programs move from qualification to volume production. The risk is that the move reflects a concentrated customer ramp or channel replenishment rather than a broad platform win; order backlog, customer concentration and gross-margin progression are the needed confirmation points over the next two earnings reports. ONON's long-dated targets and repurchase authorization improve downside support, but a premium consumer multiple still requires sustained full-price sell-through; GME remains a flow-driven event trade rather than an investable fundamental signal.

Key Decisions for Investors

• Maintain a 3-6 month relative-value short DGX / long UNH or XLV hedge rather than an outright healthcare short. Add only after management discloses affected Medicare revenue and margin sensitivity; cover if the quantified annualized EBIT impact is below 1% or CMS implementation is materially delayed.
• Use a 1-3 month long VICR position, sized modestly, only if the next order/backlog update confirms that the growth step-up extends beyond one customer. Target 15-25% upside from operating leverage; exit on sequential revenue growth reverting below 10% or gross margin failing to improve despite higher volume.
• Do not chase BABA on the data-center target. Monitor quarterly cloud capex, cloud revenue growth and segment profitability; a widening capex-to-cloud-revenue gap would favor a short BABA versus a long China data-center equipment basket, while verified accelerating cloud monetization would invalidate that view.
• For ONON, prefer accumulating on post-event weakness rather than buying the target-driven rally, with a 6-18 month horizon. The thesis requires gross margin to hold near management's long-run framework while sales growth remains above the implied path; sustained promotional activity or a material cut to sales guidance is the stop signal.
• Avoid directional GME exposure despite insider-purchase signaling; treat any spike as an opportunity to sell volatility only where borrow availability and risk limits permit, since the position has no identifiable earnings catalyst or valuation anchor.